Movement Disorder News and Research

Latest Movement Disorder News and Research

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

24 Mar 2011

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.

17 Mar 2011

65-year-old woman receives new neurostimulator implant for deep brain stimulation therapy

A 65-year-old woman with Parkinson's disease became the first patient in the United States to receive a new device for deep brain stimulation (DBS) therapy.

17 Mar 2011

Gene therapy holds promise for Parkinson's treatment

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Medtronic introduces Activa SC deep brain stimulation system in the U.S. and Europe

With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.

17 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

Positive top-line results from IPX066 Phase III study in patients with PD

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson's Disease Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release carbidopa-levodopa in advanced PD patients experiencing motor fluctuations.

15 Mar 2011

St. Joseph's Hospital launches new neuromodulation center in Barrow

St. Joseph's Hospital and Medical Center's Barrow Neurological Institute has received a $10.1 million donation, the largest single gift in the organization's history and one of the biggest ever given to any Arizona hospital.

10 Mar 2011

Researcher launches new DBS clinical trial to pinpoint brain activity in depressed people

A top medical researcher at Barrow Neurological Institute at St. Joseph's Hospital in Phoenix, Arizona, has launched a clinical trial to pinpoint brain activity in depressed people by using scientifically designed sad and heartrending photos and music.

10 Mar 2011

First recording of cortically induced neural activity of basal ganglia in Parkinson's disease, dystonia during DBS

Movement disorders such as Parkinson's diseases and dystonia are caused by abnormal neural activity of the basal ganglia located deep in the brain. The basal ganglia are connected to the cerebral cortex in the brain surface through complex neural circuits.

10 Mar 2011

Noninvasive MR-guided focused ultrasound successfully treats essential tremor

A new chapter in medical history opened days ago when noninvasive MR-guided focused ultrasound was used to successfully treat a patient with essential tremor (ET), a progressive neurological disorder that affects millions of people worldwide and causes involuntary shaking of the hands, head, face, eyelids, voice or other muscles.

10 Mar 2011

Unique gene therapy to combat Parkinson's disease

Physicians at Rush University Medical Center are testing a unique gene therapy product called CERE-120 to evaluate if its use can improve the symptoms of Parkinson's disease. Rush is one of 11 sites in the U.S. and the only site in Illinois enrolling patients into the new, double-blinded trial.

9 Mar 2011

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Omeros Corporation today announced that its exclusive license to phosphodiesterase 7 inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use.

23 Feb 2011

Amphetamine linked to development of Parkinson’s disease

New research suggests that taking prescription amphetamines may raise the risk of developing Parkinson’s disease later. But, the researchers noted that the study did not prove a cause-and-effect relationship and further investigation is warranted. The research was released Feb. 19, and is scheduled to be presented in April at the American Academy of Neurology’s annual meeting in Honolulu.

21 Feb 2011

Deep brain stimulation therapy promising against severe OCD

When obsessive-compulsive disorder is of crippling severity and drugs and behavior therapy can't help, there has been for just over a year a thread - or rather a wire - of hope. By inserting a thin electrode deep into the brain, doctors can precisely deliver an electrical current to a cord of the brain's wiring and soften the severity of the symptoms. "Deep brain stimulation" therapy for OCD won Food and Drug Administration approval in 2009 for extreme cases under its humanitarian device exemption.

19 Feb 2011

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.

17 Feb 2011

WINCS detects and measures serotonin levels in brain through deep brain stimulation

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System (WINCS) can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

16 Feb 2011

New research shows link between two pesticides and Parkinson's disease

New research shows a link between use of two pesticides, rotenone and paraquat, and Parkinson's disease. People who used either pesticide developed Parkinson's disease approximately 2.5 times more often than non-users.

14 Feb 2011

Preladenant may offer new supplemental treatment for Parkinson's disease: Study

Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy, an international study led by the University of South Florida found.

11 Feb 2011

Movement Disorder News and Research

Latest Movement Disorder News and Research

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

65-year-old woman receives new neurostimulator implant for deep brain stimulation therapy

Gene therapy holds promise for Parkinson's treatment

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Medtronic introduces Activa SC deep brain stimulation system in the U.S. and Europe

Omeros fourth quarter net loss increases to $7.2 million

Positive top-line results from IPX066 Phase III study in patients with PD

St. Joseph's Hospital launches new neuromodulation center in Barrow

Researcher launches new DBS clinical trial to pinpoint brain activity in depressed people

First recording of cortically induced neural activity of basal ganglia in Parkinson's disease, dystonia during DBS

Noninvasive MR-guided focused ultrasound successfully treats essential tremor

Unique gene therapy to combat Parkinson's disease

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Amphetamine linked to development of Parkinson’s disease

Deep brain stimulation therapy promising against severe OCD

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

WINCS detects and measures serotonin levels in brain through deep brain stimulation

New research shows link between two pesticides and Parkinson's disease

Preladenant may offer new supplemental treatment for Parkinson's disease: Study

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Movement Disorder News and Research

Latest Movement Disorder News and Research

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in